Adaptive Capital PartnersMayo Foundation For Medical ResearchWe Venture Capitalshe1KClavystBioSeeds CapitalGreenwillow Capital ManagementShe1 KClavyst Bio
Description
Respiree, a health tech firm focusing on AI platforms for disease management, has closed a US$11.6 million Series A financing round. The round was led by We Venture Capital and ClavystBio, with participation from other investors. Proceeds will be used to enhance Respiree's commercial team and expand its presence in the U.S. healthcare market
Company Information
Company
Respiree
Location
Houston, Texas, United States
About
Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare’s care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA).
Fundz sees it the moment Respiree raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
HoustonInformation TechnologyBiotechnologyHealth CareArtificial IntelligenceMachine Learning